Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Nov 9, 2016 · 10-Q · 40 days after period end · 0001564590-16-028480
| Metric | Q3 2016 | Q3 2015 |
|---|---|---|
| Net Income | -$6.24M | -$3.41M |
| EPS Diluted | -$0.47 | -$5.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end
